Botry-Zen changes mind about delisting, will shift to NZAX
Dec. 15 - Botry-Zen Ltd., the unprofitable maker of biological control agents that was going to delist from the NZX and
put its shares on the Unlisted platform, said it will now seek to move to the NZAX market for small caps.
The company made the decision after discussions with the NZX. Moving from its main board to the NZAX “offers material
cost savings and increased flexibility, while ensuring continuing transparency to shareholders and best governance
practice,” it said in a statement.
The biotech company had to quickly find a sympathetic investor this year after production of its BOTRY-ZEN product was
disrupted by manufacturing glitches and it appealed unsuccessfully to existing shareholders for more cash. Claus Hartge,
a Hamburg-based businessman, came to the rescue by agreeing to buy 10.4 million shares at 2 cents apiece.
Today, the company said it appointed Stephen Lorimer as general and technical manager starting next year.
Last month, the company posted a first-half loss of NZ$1.2 million, from a loss of NZ$544,000 a year earlier and said
it still needs more capital.
The companywas set up in 2001 to develop and commercialise biological control agents. It owns an exclusive licence to
technology developed with the Horticulture Food Research Institute of New Zealand, Winegrape Tech and Zenith Technology
Corp.
The stock last traded on Dec. 3 at 1.7 cents and is down 58% this year.
(Businesswire)
ENDS